{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:24:25Z","timestamp":1771457065292,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Gene Therapies, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s12325-023-02685-w","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T08:02:07Z","timestamp":1696060927000},"page":"5315-5337","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Patient and Caregiver Outcomes After Onasemnogene Abeparvovec Treatment: Findings from the Cure SMA 2021 Membership Survey"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5369-497X","authenticated-orcid":false,"given":"Walter","family":"Toro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihaela","family":"Georgieva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"LaMarca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanane","family":"Akbarnejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Dabbous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,30]]},"reference":[{"issue":"4","key":"2685_CR1","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831\u201346. https:\/\/doi.org\/10.1016\/j.ncl.2015.07.004.","journal-title":"Neurol Clin"},{"issue":"2","key":"2685_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s13311-014-0314-x","volume":"12","author":"MA Farrar","year":"2015","unstructured":"Farrar MA, Kiernan MC. The genetics of spinal muscular atrophy: progress and challenges. Neurotherapeutics. 2015;12(2):290\u2013302. https:\/\/doi.org\/10.1007\/s13311-014-0314-x.","journal-title":"Neurotherapeutics"},{"key":"2685_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D\u2019Amico","year":"2011","unstructured":"D\u2019Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6:71. https:\/\/doi.org\/10.1186\/1750-1172-6-71.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2685_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho M, Bernal S, Al\u00edas L, et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord. 2018;28(3):208\u201315. https:\/\/doi.org\/10.1016\/j.nmd.2018.01.003.","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"2685_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.nmd.2015.04.009","volume":"25","author":"R Finkel","year":"2015","unstructured":"Finkel R, Bertini E, Muntoni F, Mercuri E. 209th ENMC international workshop: outcome measures and clinical trial readiness in spinal muscular atrophy 7\u20139 November 2014, Heemskerk, the Netherlands. Neuromuscul Disord. 2015;25(7):593\u2013602. https:\/\/doi.org\/10.1016\/j.nmd.2015.04.009.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"2685_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017;12(1):124. https:\/\/doi.org\/10.1186\/s13023-017-0671-8.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2685_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13023-021-01695-7","volume":"16","author":"T Dangouloff","year":"2021","unstructured":"Dangouloff T, Botty C, Beaudart C, Servais L, Hiligsmann M. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis. 2021;16(1):47. https:\/\/doi.org\/10.1186\/s13023-021-01695-7.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2685_CR8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1212\/WNL.0000000000009715","volume":"95","author":"GM Chambers","year":"2020","unstructured":"Chambers GM, Settumba SN, Carey KA, et al. Prenusinersen economic and health-related quality of life burden of spinal muscular atrophy. Neurology. 2020;95(1):e1\u201310. https:\/\/doi.org\/10.1212\/WNL.0000000000009715.","journal-title":"Neurology"},{"issue":"23","key":"2685_CR9","doi-asserted-by":"publisher","first-page":"8989","DOI":"10.3390\/ijerph17238989","volume":"17","author":"I Aranda-Reneo","year":"2020","unstructured":"Aranda-Reneo I, Pe\u00f1a-Longobardo LM, Oliva-Moreno J, et al. The burden of spinal muscular atrophy on informal caregivers. Int J Environ Res Public Health. 2020;17(23):8989. https:\/\/doi.org\/10.3390\/ijerph17238989.","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"2685_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3233\/JND-200610","volume":"8","author":"HJ McMillan","year":"2021","unstructured":"McMillan HJ, Gerber B, Cowling T, et al. Burden of spinal muscular atrophy (SMA) on patients and caregivers in Canada. J Neuromuscul Dis. 2021;8(4):553\u201368. https:\/\/doi.org\/10.3233\/JND-200610.","journal-title":"J Neuromuscul Dis"},{"issue":"15 Suppl","key":"2685_CR11","first-page":"P4.-016","volume":"92","author":"A Callan","year":"2019","unstructured":"Callan A, Nallagangula TK, Jawla S, de Pommerol HJ, Risson V. Spinal muscular atrophy: a review of epidemiology, burden and unmet needs (P4.4\u2013016). Neurology. 2019;92(15 Suppl):P4.-016.","journal-title":"Neurology"},{"key":"2685_CR12","unstructured":"The US Food and Drug Administration. Summary basis for regulatory action\u2014Zolgensma. 2019 [updated 2019 May 24]. https:\/\/www.fda.gov\/media\/127961\/download. Accessed 2023 Apr 11."},{"key":"2685_CR13","unstructured":"European Medicines Agency. Summary of product characteristics - onasemnogene abeparvovec. 2020 [updated 17 May 2022]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zolgensma-epar-product-information_en.pdf. Accessed 2023 Apr 11."},{"issue":"5","key":"2685_CR14","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1007\/s12325-019-00923-8","volume":"36","author":"O Dabbous","year":"2019","unstructured":"Dabbous O, Maru B, Jansen JP, et al. Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type\u00a01. Adv Ther. 2019;36(5):1164\u201376. https:\/\/doi.org\/10.1007\/s12325-019-00923-8.","journal-title":"Adv Ther"},{"issue":"4","key":"2685_CR15","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284\u201393. https:\/\/doi.org\/10.1016\/S1474-4422(21)00001-6.","journal-title":"Lancet Neurol"},{"issue":"10","key":"2685_CR16","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","volume":"20","author":"E Mercuri","year":"2021","unstructured":"Mercuri E, Muntoni F, Baranello G, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type\u00a01 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(10):832\u201341. https:\/\/doi.org\/10.1016\/S1474-4422(21)00251-9.","journal-title":"Lancet Neurol"},{"issue":"7","key":"2685_CR17","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","volume":"78","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Lehman KJ, et al. Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 2021;78(7):834\u201341. https:\/\/doi.org\/10.1001\/jamaneurol.2021.1272.","journal-title":"JAMA Neurol"},{"issue":"7","key":"2685_CR18","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type\u00a01: the phase III SPR1NT trial. Nat Med. 2022;28(7):1381\u20139. https:\/\/doi.org\/10.1038\/s41591-022-01866-4.","journal-title":"Nat Med"},{"issue":"7","key":"2685_CR19","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the phase III SPR1NT trial. Nat Med. 2022;28(7):1390\u20137. https:\/\/doi.org\/10.1038\/s41591-022-01867-3.","journal-title":"Nat Med"},{"issue":"3","key":"2685_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3233\/JND-190403","volume":"6","author":"SA Al-Zaidy","year":"2019","unstructured":"Al-Zaidy SA, Kolb SJ, Lowes L, et al. AVXS-101 (onasemnogene abeparvovec) for SMA1: comparative study with a prospective natural history cohort. J Neuromuscul Dis. 2019;6(3):307\u201317. https:\/\/doi.org\/10.3233\/JND-190403.","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"2685_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ppul.24203","volume":"54","author":"S Al-Zaidy","year":"2019","unstructured":"Al-Zaidy S, Pickard AS, Kotha K, et al. Health outcomes in spinal muscular atrophy type\u00a01 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2019;54(2):179\u201385. https:\/\/doi.org\/10.1002\/ppul.24203.","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"2685_CR22","doi-asserted-by":"publisher","first-page":"1889841","DOI":"10.1080\/20016689.2021.1889841","volume":"9","author":"R Dean","year":"2021","unstructured":"Dean R, Jensen I, Cyr P, et al. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma\u00ae) in spinal muscular atrophy type\u00a01 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Mark Access Health Policy. 2021;9(1):1889841. https:\/\/doi.org\/10.1080\/20016689.2021.1889841.","journal-title":"J Mark Access Health Policy"},{"issue":"1","key":"2685_CR23","doi-asserted-by":"publisher","first-page":"1601484","DOI":"10.1080\/20016689.2019.1601484","volume":"7","author":"DC Malone","year":"2019","unstructured":"Malone DC, Dean R, Arjunji R, et al. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type\u00a01 patients. J Mark Access Health Policy. 2019;7(1):1601484. https:\/\/doi.org\/10.1080\/20016689.2019.1601484.","journal-title":"J Mark Access Health Policy"},{"key":"2685_CR24","unstructured":"Dabbous O, Georgieva M, Toro W, et al. Real-world outcomes of disease-modifying treatments for pediatric patients with spinal muscular atrophy: Interim analysis of a US chart review study. Poster presented at the 2022 Muscular Dystrophy Association Clinical and Scientific Congress; 2022 March 13\u201316; Nashville, TN, USA."},{"issue":"1","key":"2685_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","volume":"6","author":"C Wei\u00df","year":"2022","unstructured":"Wei\u00df C, Ziegler A, Becker LL, et al. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24\u00a0months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2022;6(1):17\u201327. https:\/\/doi.org\/10.1016\/S2352-4642(21)00287-X.","journal-title":"Lancet Child Adolesc Health"},{"key":"2685_CR26","unstructured":"Servais L, De Vivo DC, Kirschner J, et al. Effectiveness and safety of onasemnogene abeparvovec in older patients with spinal muscular atrophy: real-world outcomes from the RESTORE registry. Poster presented at 2022 Muscular Dystrophy Association Clinical and Scientific Congress, March 13\u201316, 2022, Nashville, TN, USA."},{"issue":"2","key":"2685_CR27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3233\/JND-170292","volume":"5","author":"L Belter","year":"2018","unstructured":"Belter L, Cook SF, Crawford TO, et al. An overview of the Cure SMA membership database: highlights of key demographic and clinical characteristics of SMA members. J Neuromuscul Dis. 2018;5(2):167\u201376. https:\/\/doi.org\/10.3233\/JND-170292.","journal-title":"J Neuromuscul Dis"},{"key":"2685_CR28","unstructured":"Belter L, Whitmire S, Schroth M. State of SMA. 2021 [updated 2021 December]. https:\/\/www.curesma.org\/wp-content\/uploads\/2022\/06\/9042022_State-of-SMA_vweb.pdf. Accessed 2023 Apr 11."},{"issue":"1","key":"2685_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s13023-020-01498-2","volume":"15","author":"L Belter","year":"2020","unstructured":"Belter L, Cruz R, Jarecki J. Quality of life data for individuals affected by spinal muscular atrophy: a baseline dataset from the Cure SMA Community Update Survey. Orphanet J Rare Dis. 2020;15(1):217. https:\/\/doi.org\/10.1186\/s13023-020-01498-2.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2685_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3233\/JND-200563","volume":"8","author":"L Belter","year":"2021","unstructured":"Belter L, Jarecki J, Reyna SP, et al. The Cure SMA Membership Surveys: highlights of key demographic and clinical characteristics of individuals with spinal muscular atrophy. J Neuromuscul Dis. 2021;8(1):109\u201323. https:\/\/doi.org\/10.3233\/JND-200563.","journal-title":"J Neuromuscul Dis"},{"key":"2685_CR31","unstructured":"Centers for Disease Control and Prevention. Developmental milestone checklists. 2021. https:\/\/www.cdc.gov\/ncbddd\/actearly\/pdf\/FULL-LIST-CDC_LTSAE-Checklists2021_Eng_FNL2_508.pdf. Accessed 2023 Apr 11."},{"issue":"2","key":"2685_CR32","first-page":"43","volume":"20","author":"Y Feng","year":"2009","unstructured":"Feng Y, Bernier J, McIntosh C, Orpana H. Validation of disability categories derived from Health Utilities Index Mark 3 scores. Health Rep. 2009;20(2):43\u201350.","journal-title":"Health Rep"},{"key":"2685_CR33","doi-asserted-by":"crossref","unstructured":"CADTH Common Drug Reviews. Clinical Review Report: Nusinersen (Spinraza). Canadian Agency for Drugs and Technologies in Health; 2019 [updated 2019 Apr]. https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/clinical\/sr0576-spinraza-resubmission-clinical-report.pdf. Accessed 2023 Apr 11.","DOI":"10.51731\/cjht.2022.496"},{"key":"2685_CR34","unstructured":"Reilley Associates. Work Productivity and Activity Impairment. WPAI: GH V2.0. 2004. http:\/\/www.reillyassociates.net\/WPAI_GH.html. Accessed 2023 Apr 11."},{"key":"2685_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.06.007","volume":"100","author":"SA Al-Zaidy","year":"2019","unstructured":"Al-Zaidy SA, Mendell JR. From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type\u00a01. Pediatr Neurol. 2019;100:3\u201311. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2019.06.007.","journal-title":"Pediatr Neurol"},{"key":"2685_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-022-00341-6","author":"I Bitetti","year":"2022","unstructured":"Bitetti I, Lanzara V, Margiotta G, Varone A. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study. Gene Ther. 2022. https:\/\/doi.org\/10.1038\/s41434-022-00341-6.","journal-title":"Gene Ther"},{"issue":"3","key":"2685_CR37","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/acn3.51519","volume":"9","author":"AM D\u2019Silva","year":"2022","unstructured":"D\u2019Silva AM, Holland S, Kariyawasam D, et al. Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy. Ann Clin Transl Neurol. 2022;9(3):339\u201350. https:\/\/doi.org\/10.1002\/acn3.51519.","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"2685_CR38","doi-asserted-by":"publisher","first-page":"e20200729","DOI":"10.1542\/peds.2020-0729","volume":"146","author":"MA Waldrop","year":"2020","unstructured":"Waldrop MA, Karingada C, Storey MA, et al. Gene therapy for spinal muscular atrophy: safety and early outcomes. Pediatrics. 2020;146(3):e20200729. https:\/\/doi.org\/10.1542\/peds.2020-0729.","journal-title":"Pediatrics"},{"issue":"4","key":"2685_CR39","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3233\/JND-221531","volume":"10","author":"KE McGrattan","year":"2023","unstructured":"McGrattan KE, Shell RD, Hurst-Davis R, et al. Patients with spinal muscular atrophy type\u00a01 achieve and maintain bulbar function following onasemnogene abeparvovec treatment. J Neuromuscul Dis. 2023;10(4):531\u201340. https:\/\/doi.org\/10.3233\/JND-221531.","journal-title":"J Neuromuscul Dis"},{"issue":"3","key":"2685_CR40","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/mus.27116","volume":"63","author":"E Chen","year":"2021","unstructured":"Chen E, Dixon S, Naik R, et al. Early experiences of nusinersen for the treatment of spinal muscular atrophy: results from a large survey of patients and caregivers. Muscle Nerve. 2021;63(3):311\u20139. https:\/\/doi.org\/10.1002\/mus.27116.","journal-title":"Muscle Nerve"},{"key":"2685_CR41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12962-020-00234-8","volume":"18","author":"P Thokala","year":"2020","unstructured":"Thokala P, Stevenson M, Kumar VM, Ren S, Ellis AG, Chapman RH. Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US. Cost Eff Resour Alloc. 2020;18:41. https:\/\/doi.org\/10.1186\/s12962-020-00234-8.","journal-title":"Cost Eff Resour Alloc"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02685-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02685-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02685-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T11:08:44Z","timestamp":1698404924000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02685-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,30]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2685"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02685-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,30]]},"assertion":[{"value":"19 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Walter Toro, Anish Patel, and Omar Dabbous are Novartis Gene Therapies, Inc., employees and own Novartis stock or other equities. Nicole LaMarca was an employee of Novartis Gene Therapies, Inc., at the time of the study and analysis. Min Yang, Annika Anderson, and Hanane Akbarnejad are employees of Analysis Group, Inc., which has received consulting fees from Novartis Gene Therapies, Inc., for this research. Mihaela Georgieva was an employee of Analysis Group, Inc., at the time of the study and analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data from the 2021 Cure SMA Membership Survey were used for this study. Institutional review board approval was obtained for the membership survey and all data were de-identified prior to analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}